- Home
- GILD vs LMT Comparison
GILD vs LMT Comparison
Compare GILD & LMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- LMT
- Stock Information
- Founded
- GILD 1987
- LMT 1912
- Country
- GILD United States
- LMT United States
- Employees
- GILD N/A
- LMT 122000
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- LMT Military/Government/Technical
- Sector
- GILD Health Care
- LMT Industrials
- Exchange
- GILD Nasdaq
- LMT Nasdaq
- Market Cap
- GILD 113.0B
- LMT 116.2B
- IPO Year
- GILD 1992
- LMT N/A
- Fundamental
- Price
- GILD $91.84
- LMT $490.37
- Analyst Decision
- GILD Buy
- LMT Buy
- Analyst Count
- GILD 26
- LMT 12
- Target Price
- GILD $98.17
- LMT $588.25
- AVG Volume (30 Days)
- GILD 6.6M
- LMT 1.2M
- Earning Date
- GILD 02-11-2025
- LMT 01-28-2025
- Dividend Yield
- GILD 3.35%
- LMT 2.69%
- EPS Growth
- GILD N/A
- LMT 0.98
- EPS
- GILD 0.10
- LMT 27.67
- Revenue
- GILD $28,299,000,000.00
- LMT $71,295,000,000.00
- Revenue This Year
- GILD $6.50
- LMT $6.49
- Revenue Next Year
- GILD $0.36
- LMT $3.88
- P/E Ratio
- GILD $908.39
- LMT $17.72
- Revenue Growth
- GILD 3.31
- LMT 5.33
- 52 Week Low
- GILD $62.07
- LMT $413.92
- 52 Week High
- GILD $98.90
- LMT $618.95
- Technical
- Relative Strength Index (RSI)
- GILD 51.58
- LMT 49.80
- Support Level
- GILD $90.82
- LMT $461.24
- Resistance Level
- GILD $93.07
- LMT $487.76
- Average True Range (ATR)
- GILD 1.54
- LMT 7.86
- MACD
- GILD -0.03
- LMT 3.49
- Stochastic Oscillator
- GILD 56.28
- LMT 90.58
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About LMT Lockheed Martin Corporation
Lockheed Martin is the world's largest defense contractor and has dominated the Western market for high-end fighter aircraft since it won the F-35 Joint Strike Fighter program in 2001. Lockheed's largest segment is aeronautics, which derives upward of two-thirds of its revenue from the F-35. Lockheed's remaining segments are rotary and mission systems, mainly encompassing the Sikorsky helicopter business; missiles and fire control, which creates missiles and missile defense systems; and space systems, which produces satellites and receives equity income from the United Launch Alliance joint venture.